NCT07520760 2026-04-09
MBC-EA
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
13 trialsNCT07330544 2026-01-09
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05582499 2025-08-22
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT06874933 2025-08-12
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06992336 2025-05-28
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06678230 2024-11-07
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
Phase 2 Unknown
NCT06547476 2024-08-09
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting
NCT05296577 2023-09-25
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT05206656 2022-11-23
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Hunan Cancer Hospital
Phase 2 Completed
NCT05558722 2022-09-28
ACNTBC
Xijing Hospital
Phase 2 Unknown
NCT04975451 2021-07-27
ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Guangdong Women and Children Hospital
Phase 2 Unknown
NCT04936295 2021-06-23
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04002284 2020-07-29
Anlotinib in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Completed